Side-effects in women treated with adjuvant endocrine therapy for breast cancer

• DOI: 10.1016/j.breast.2025.104416
• Publication Date: 2025-02-11T08:00:49Z
• Authors: L.M. Rademaker; R. Gal; A.M. May; M.C.T. Batenburg; F. van der Leij; R.M. Bijlsma; H.M. Verkooijen; A. Doeksen; M.F. Ernst; D.J. Evers; C.C. van der Pol; E.M. Monninkhof
• Keywords: Adjuvant Therapy

Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort gain insight into prevalence of side-effects and its association premature discontinuation. Almost all current therapy users experienced (92.7 %), most frequent were vasomotor- musculoskeletal symptoms. The reported reason for discontinuation was (88.1 %). Former treatment chemotherapy associated more (97.2 % vs 82.5 %, ORadj 6.31), but less (18.6 28.6 p-value 0.016).